中文 English

PlasAimTM Lung Cancer Non-invasive Assay

Detection method

The highly sensitive library preparation technology and efficient target enrichment method used with this assay, compared to PCR and first-generation sequencing methods, is able to simultaneously detect mutations in the full coding sequence of multiple genes. More genetic information can be obtained from limited amounts patient samples and quickly. 

Test significance

This assay provides guidance for target treatment related to mutations, insertions/deletions, amplification, and fusions in non-small cell lung cancer, including Sunitinib and Ceritinib.

Product advantage

1) Scan all mutation hotspot coding regions using ddCAP technology.
2) Sequencing depth of at least 10,000X with 0.01% analytical sensitivity.
3) Simultaneous detection of SNVs, indels, CNVs and fusions.



Detection of genes

Tumor genes(12)

  • ALK
  • BRAF
  • ERBB2
  • EGFR
  • FGFR1
  • MET
  • KRAS
  • NRAS
  • PIK3CA
  • TP53
  • RET
  • ROS1

Applicable to cancer patients

This assay is applicable to common cancers such as lung cancer, breast cancer, colorectal cancer, esophageal cancer, and ovarian cancer when tissue samples cannot be evaluated. The product can be applied to:
Cancer patients treated with targeted therapy , in order to identify the best drug.
Cancer patients who failed routine treatment, in order to find the cause of drug resistance or potential target sites.  




Test procedure

*Product is for research use only.